Welcome, Guest
Username: Password: Remember me

TOPIC: SVFC - IntelliCell BioSciences, Inc

6 years 2 months ago #1692

  • Diggity
  • Diggity's Avatar
  • Offline
  • Platinum Boarder
  • Posts: 1724
  • Karma: -10
IntelliCell BioSciences, Inc. Appoints Dr. Sigmund Norr to Its Board of Advisors


NEW YORK, NY--(Marketwire - Oct 19, 2011) - IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today it has appointed pediatrician, Dr. Sigmund Norr to its Board of Advisors. Dr. Norr, of the Cleveland Clinic, joins ten other prominent doctors on the Company's Board of Advisors.

Sigmund Carl Norr, Ph.D., M.D., practices general pediatrics and serves as Section Head of Pediatrics at the Willoughby Hills Family Health Center. Prior to joining the Cleveland Clinic, Dr. Norr was Medical Director and staff physician at MEDGroup in Fairlawn, Ohio. Preceding that, Dr. Norr served in a number of roles with Ohio Permanente Medical Group, including Medical Director of the Alcohol Chemical Dependency Program, and Chief of the Department of Pediatric and Adolescent Medicine.

He is board-certified in pediatrics and addiction medicine. Dr. Norr received his undergraduate degree in biology from the University of Pittsburgh. He completed a doctorate in developmental cell biology at Case Western Reserve University and earned his medical degree from the University of Miami. He completed an internship and residency in pediatric medicine at Rainbow Babies and Children's Hospital in Cleveland, Ohio.

Dr. Norr is a member of the American Academy of Pediatrics. His specialty interests include ambulatory pediatrics and adolescent medicine, ADHD, asthma, and adolescent chemical dependency. He has published and spoken on the topics of neurobiology and cell biology.

"We welcome Dr. Norr aboard and look forward to what we're sure will be a substantive contribution to IntelliCell given his extensive knowledge of cell biology and pediatric medicine," stated IntelliCell Chairman and CEO, Dr. Steven Victor.

The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the US FDA published its laws on autologous stem cells the field has expanded rapidly. Currently, doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments.

http://www.marketwire.com/press-release/intellicell-biosciences-inc-appoints-dr-sigmund-norr-to-its-board-of-advisors-otcqb-svfc-1574934.htm
The administrator has disabled public write access.

6 years 2 months ago #1591

  • Diggity
  • Diggity's Avatar
  • Offline
  • Platinum Boarder
  • Posts: 1724
  • Karma: -10
IntelliCell BioSciences, Inc. Appoints Jack Schneider to Its Board of Advisors


NEW YORK, NY--(Marketwire - Oct 17, 2011) - IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today it has appointed media veteran, Jack Schneider to its Board of Advisors. Jack Schneider joins ten other luminaries on the Company's Board of Advisors.

Mr. Jack Schneider served as Managing Director of Allen & Co. LLC for more than 30 years. Mr. Schneider has also been on the Board of the National Mentoring Partnership for 12 years, and he has served as Chairman of the Buoniconti Fund to Cure Paralysis for 25 years. He serves on the Board of Autism Speaks. His addition to the IntelliCell team brings an unparalleled level of experience and new relationships to the company at a time when regenerative medicine could become the defining term for innovation and new forms of treatment in the fast evolving medical field. He also has a wealth of M&A experience from Allen & Co. and his long-term relationships with other leaders in forward-thinking communities concerned with neurological disorders opens many doors to new opportunities for IntelliCell.

"I am delighted that Jack Schneider has joined the Board of Advisors and I am sure that his wealth of knowledge and interest in Paralysis and Autism will help guide us into new and exciting frontiers regarding the use of our technology," stated IntelliCell Chairman and CEO, Dr. Steven Victor.

"I am excited about the technology of IntelliCell BioSciences as it pertains to possible treatments of paralysis and autism," according to Jack Schneider.

The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the US FDA published its laws on autologous stem cells the field has expanded rapidly. Currently, doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments.

http://www.marketwire.com/press-release/intellicell-biosciences-inc-appoints-jack-schneider-to-its-board-of-advisors-otcqb-svfc-1573640.htm
The administrator has disabled public write access.

6 years 2 months ago #1590

  • Diggity
  • Diggity's Avatar
  • Offline
  • Platinum Boarder
  • Posts: 1724
  • Karma: -10
IntelliCell BioSciences Out to Shake Up Regenerative Medicine With Disruptive Technology and Game Plan


LOS ANGELES, CA--(Marketwire - Sep 28, 2011) - Shares of the tightly held IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) have been starting to climb since announcing their arrival as a disruptive stem cell harvesting technology firm just a few short weeks ago. The regenerative medicine industry is starting to take notice, but it appears investors are too.

BioMedReports first told readers about this company in a report from the Rodman & Renshaw Conference, and shares have climbed from $3 to over $4 since then. Even in these very anemic market conditions, speculators are starting to take positions after hearing about the potential of the IntelliCell platform.

In addition, the Company just announced that they executed an exclusive supply and sale agreement with Millipore Corporation, a global leader in innovative tools and technologies for bio-manufacturing and life science research, to sell and distribute the guava® flow cytometry platform into the area of stromal vascular fraction.

The collaboration with Millipore is expected to streamline the development of IntelliCell's tissue processing centers throughout the United States as it continues to expand and experience growth in demand for the cells it is able to source from fatty tissue.

As we understand it, the company is rapidly expanding the number of centers throughout the United States and multiple positive announcements should follow. These very unique centers will offer patients the opportunity to use their own adipose (fat) stem cells for treatments as prescribed by their own doctors. Under FDA 361, patients are allowed to use their own stem cells for just about any indication, so long as the use of those cells is autologous (a situation in which the donor and recipient are the same person), the stem cells are minimally manipulated, and the procedure takes place during the same office visit. Even without FDA approval -- which can take years -- IntelliCell™ BioScience aims to work within FDA 361 guidelines and claims that they are fully FDA Compliant on their website and presentation materials.

As we told you in our report, this company represents a game changing opportunity for U.S. based patients to undergo various stem cell therapies using their own stem cells without having to travel abroad or wait for further FDA approvals.

BioMedReports expect that this company -- already one of the only true revenue generating stem cell plays in the market -- will surpass the $30+ million in revenues generated last year by a privately held company based in Plymouth, Mass called Harvest Technologies Corporation.

That company was in the process of commercializing a far more painful (and arguably less effective), point-of-care technology with doctors. Using the Harvest Technology platform, physicians harvested stem cells from a patient's own bone marrow. Harvest was recently acquired by a U.S. subsidiary of Japan's Terumo Corporation -- one of the world's leading medical device manufacturers with $3.4 billion in sales and operations in more than 160 countries in a stock for stock transaction worth $70 million.

The market potential for IntelliCell BioSciences is far more attractive, and we are hearing rumors that various sports franchises may be looking to treat the injuries of pro athletes using the IntelliCell platform within the offices of their own team doctors. No surprise if true, since they have pro sports teams physicians on their advisory board.

The use of autologous adipose stem cells for a growing variety of indications may appear new and exciting in medicine here in the U.S, but the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the U.S. FDA published its laws on autologous stem cells the field has expanded rapidly. If you are looking for a stem cell play that isn't going to make you wait 5+ years for FDA approval, this may be it.

A new report featuring more information about IntelliCell BioSciences, Inc. may be read at:

http://biomedreports.com/2011092879492/regenerative-medicine-industry-taking-notice-of-intellicell-biosciences.html

In addition, investors may access BioMedReports' new complete FDA Calendar and database of clinical trials and world-wide regulatory decisions for use as a tool in more profitable trading by visiting:

http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html

News developments and live healthcare sector updates are available constantly via twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com

http://www.marketwire.com/press-release/intellicell-biosciences-out-shake-up-regenerative-medicine-with-disruptive-technology-otcqb-svfc-1566443.htm
The administrator has disabled public write access.

6 years 3 months ago #954

  • Diggity
  • Diggity's Avatar
  • Offline
  • Platinum Boarder
  • Posts: 1724
  • Karma: -10
IntelliCell BioSciences, Inc. Announces It Has Signed an Exclusive Supply and Sale Agreement With Millipore Corporation


NEW YORK, NY--(Marketwire - Sep 26, 2011) - IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose-derived adult stem cells, announced today that it has executed an exclusive supply and sale agreement with Millipore Corporation, a global leader in innovative tools and technologies for bio-manufacturing and life science research, to sell and distribute the guava® flow cytometry platform into the area of SVF. This collaboration will streamline the development of IntelliCell's tissue processing centers throughout the United States as it continues to expand and experience growth in demand for the cells it is able to source from fatty tissue.

The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the U.S. FDA published its laws on autologous stem cells the field has expanded rapidly. Currently, numerous doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments. In addition, numerous studies have been conducted on animals for veterinary applications over the last few decades.

"This is a phenomenal step in the right direction for our company and we welcome the opportunity to work with Millipore. The exclusive agreement with Millipore to supply and sell their cutting-edge guava flow cytometer, combined with our proprietary process which has achieved unprecedented yields of stromal vascular fraction without the use of chemical additives such as enzymes, gives us a highly significant advantage in creating the gold standard for the separation of SVF from fat. As the only company to use precise methods of counting cells and checking specimens for cell viability, dead cells, or debris, this is yet another milestone in our quest to become market leader in the area of separation of SVF, which greatly differentiates us from all other companies that manufacture these cells," stated IntelliCell Chairman and CEO, Dr. Steven Victor.

http://www.marketwire.com/press-release/intellicell-biosciences-inc-announces-it-has-signed-exclusive-supply-sale-agreement-otcqb-svfc-1565084.htm
The administrator has disabled public write access.

6 years 4 months ago #566

  • Diggity
  • Diggity's Avatar
  • Offline
  • Platinum Boarder
  • Posts: 1724
  • Karma: -10
IntelliCell BioSciences, Inc. Announces It Has Signed a Licensing Agreement With The PAWS Pet Company, Inc.


NEW YORK, NY--(Marketwire - Aug 30, 2011) - IntelliCell BioSciences, Inc. (OTCQX: SVFC) (PINKSHEETS: SVFC) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today that it has executed an agreement with The PAWS Pet Company, Inc., (OTCQB: PAWS) (PINKSHEETS: PAWS), the innovative pet services company. This collaboration will make SVF available to the veterinary world for use in the full-spectrum of pet applications.

The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world, the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the US FDA published its laws on autologous stem cells, the field has expanded rapidly. Currently, numerous doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments. In addition, numerous studies have been conducted on animals for veterinary applications over the last few decades.

"Our deal with The PAWS Pet Company is a very exciting advancement for veterinary medicine! With their marketing skills in the animal world and our advanced technology we have a winning formula for treating animals with 'IntelliCells' which has a high concentration of stem cells," stated IntelliCell Chairman and CEO, Dr. Steven Victor.

Dan Wiesel, Chairman and CEO of The PAWS Pet Company, added, "We are excited to be working with IntelliCell to bring their regenerative medicine treatment to the pet marketplace. Through our trusted position with both Pet Parents and Veterinarians, we will introduce a technology that we believe will improve the wellbeing of pets."

IntelliCell's adipose stem cell processing technique takes approximately 30 minutes and the stem cells can be returned to the veterinarian in the same day. Autologous Adipose stem cells are on the cutting edge of medicine and IntelliCell is excited to be one of the companies to participate in this field.

IntelliCell has developed an in-house technology where it can easily process stromal vascular cells containing a high concentration of adipose stem cells with excellent viability. At present, management believes it is the only company that does not use enzymes in processing adipose tissue and actually counts and checks the adipose stem cells they manufacture.

About IntelliCell Biosciences, Inc.

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on setting up tissue processing centers throughout the United States with managing partners. The centers will receive and employ the IntelliCell™ process to the adipose stromal vascular fraction harvested by physicians in their own offices, and then return the IntelliCells™ to the physicians the same day labeled "autologous homologous." IntelliCell has already established processing centers in New York City, Philadelphia, Dallas/Ft. Worth, and New Orleans, and has entered into a licensing agreement for a center in Palm Beach. In the future, IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212 249 3050.

About The PAWS Pet Company

The PAWS Pet Company, Inc. provides innovative pet services. Its wholly owned subsidiary Pet Airways is the only airline specifically designed for the safe and comfortable transportation of pets. Pet Airways' Pawsengers™ travel in the specially equipped main cabin of its planes -- where pets are continuously monitored by an In-Flight Pet Attendant and the climate is controlled for maximum pet comfort. With Pet Airways, pet parents can be assured their pets will be treated with tender, loving care by pet professionals throughout the journey. The airline launched flight operations in 2009 and currently serves coast-to-coast destinations across the United States, including Los Angeles, Phoenix, Denver, Omaha, Chicago, Baltimore, New York, Atlanta and Ft. Lauderdale. The company has also announced its upcoming expansion to Orlando, Dallas, Austin, Houston and St. Louis.

For more information on The PAWS Pet Company go to www.thepawspetcompany.com

http://www.marketwire.com/press-release/intellicell-biosciences-inc-announces-it-has-signed-licensing-agreement-with-the-paws-otcqx-svfc-1554963.htm
The administrator has disabled public write access.

SVFC - IntelliCell BioSciences, Inc 6 years 4 months ago #565

  • Diggity
  • Diggity's Avatar
  • Offline
  • Platinum Boarder
  • Posts: 1724
  • Karma: -10
The PAWS Pet Company and IntelliCell BioSciences to Bring Regenerative Cell Therapy to Animals


SAN JOSE, CA--(Marketwire - Aug 30, 2011) - The PAWS Pet Company, Inc. (OTCQB: PAWS) (PINKSHEETS: PAWS) or "the Company," the innovative pet services company, today announced it has entered into an exclusive license agreement with IntelliCell BioSciences, Inc., "IntelliCell" (PINKSHEETS: SVFC), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells. Per the terms of the agreement, The PAWS Pet Company is to exclusively market and sell IntelliCell's SVF solution in the veterinary market.

According to Hoovers, the U.S. veterinary services industry has annual revenues estimated at $25 billion.

"This is an important step in the development of the Company," said Dan Wiesel, Chairman and CEO of The PAWS Pet Company. "This exclusive world-wide license extends our service offering beyond the pet transportation marketplace, into the fast growing market for regenerative medicine for animals. Through our trusted position with both Pet Parents and Veterinarians, we will introduce a technology that we believe will improve the wellbeing of pets."

Dr. Steven Victor, Chairman and CEO of IntelliCell, added, "We are pleased to be working with The PAWS Pet Company in bringing our leading SVF solution to the treatment of animals. The benefits of SVF in providing stem cell counts and viability checks for each specimen processed, as well as enhanced quality and quantity of the stem cells produced, will now be available to pets."

Dr. Jeff Werber, Director of Veterinary Services with The PAWS Pet Company, commented, "SVF is a proven treatment for a number of conditions including osteoarthritis, tendon repair, ligament injuries and other traumatic and degenerative diseases. The higher cell count from a smaller tissue sample means that Pets have a faster road to recovery with SVF compared to legacy enzyme-based stem cell treatments."

About The PAWS Pet Company

The PAWS Pet Company, Inc. provides innovative pet services. Its wholly owned subsidiary Pet Airways is the only airline specifically designed for the safe and comfortable transportation of pets. Pet Airways' Pawsengers™ travel in the specially equipped main cabin of its planes -- where pets are continuously monitored by an In-Flight Pet Attendant and the climate is controlled for maximum pet comfort. With Pet Airways, pet parents can be assured their pets will be treated with tender, loving care by pet professionals throughout the journey. The airline launched flight operations in 2009 and currently serves coast-to-coast destinations across the United States, including Los Angeles, Phoenix, Denver, Omaha, Chicago, Baltimore, New York, Atlanta and Ft. Lauderdale. The company has also announced its upcoming expansion to Orlando, Dallas, Austin, Houston and St. Louis.

For more information on The PAWS Pet Company go to www.thepawspetcompany.com

About IntelliCell Biosciences, Inc.

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on setting up tissue processing centers throughout the United States with managing partners. The centers will receive and employ the IntelliCell™ process to the adipose stromal vascular fraction harvested by physicians in their own offices, and then return the IntelliCells™ to the physicians the same day labeled "autologous homologous." IntelliCell has already established processing centers in New York City, Philadelphia, Dallas/Ft. Worth, and New Orleans, and has entered into a licensing agreement for a center in Palm Beach. In the future, IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212 249 3050.

http://www.marketwire.com/press-release/paws-pet-company-intellicell-biosciences-bring-regenerative-cell-therapy-animals-otcqb-paws-1554961.htm
The administrator has disabled public write access.

Member Login